Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis.

MLA

Di Bona, Danilo, et al. “Effectiveness of Benralizumab in Severe Eosinophilic Asthma: Distinct Sub‐phenotypes of Response Identified by Cluster Analysis.” Clinical & Experimental Allergy, vol. 52, no. 2, Feb. 2022, pp. 312–23. EBSCOhost, https://doi.org/10.1111/cea.14026.

APA

Di Bona, D., Crimi, C., D’Uggento, A. M., Benfante, A., Caiaffa, M. F., Calabrese, C., Campisi, R., Carpagnano, G. E., Ciotta, D., D’Amato, M., Pelaia, C., Pelaia, G., Pellegrino, S., Scichilone, N., Scioscia, G., Ribecco, N., Spadaro, G., Valenti, G., Vatrella, A., & Crimi, N. (2022). Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis. Clinical & Experimental Allergy, 52(2), 312–323. https://doi.org/10.1111/cea.14026

Chicago

Di Bona, Danilo, Claudia Crimi, Angela Maria D’Uggento, Alida Benfante, Maria Filomena Caiaffa, Cecilia Calabrese, Raffaele Campisi, et al. 2022. “Effectiveness of Benralizumab in Severe Eosinophilic Asthma: Distinct Sub‐phenotypes of Response Identified by Cluster Analysis.” Clinical & Experimental Allergy 52 (2): 312–23. doi:10.1111/cea.14026.